Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR 2.870
-0.090 (-3.04%)
Aug 21, 2026, 5:35 PM CET
Cellectis Revenue
Cellectis had revenue of $6.90M USD in the quarter ending June 30, 2026, a decrease of -62.05%. This brings the company's revenue in the last twelve months to $63.82M, up 0.61% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$63.82M
Revenue Growth
+0.61%
P/S Ratio
3.73
Revenue / Employee
$278.70K
Employees
229
Market Cap
208.64M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
| Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
| Dec 31, 2016 | 56.45M | -6.12M | -9.78% |
| Dec 31, 2015 | 62.57M | 30.56M | 95.47% |
| Dec 31, 2014 | 32.01M | 14.51M | 82.92% |
| Dec 31, 2013 | 17.50M | -10.25M | -36.93% |
| Dec 31, 2012 | 27.74M | 7.04M | 34.00% |
| Dec 31, 2011 | 20.70M | -248.54K | -1.19% |
| Dec 31, 2010 | 20.95M | 6.11M | 41.19% |
| Dec 31, 2009 | 14.84M | -2.65M | -15.16% |
| Dec 31, 2008 | 17.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 70.85M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| DBV Technologies | 4.41M |
| ABIONYX Pharma | 4.06M |
| Adocia | 3.85M |
Cellectis News
- 16 days ago - Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline - Nasdaq
- 16 days ago - Cellectis reports Q2 adjusted EPS (35c) vs (40c) last year - TheFly
- 16 days ago - Cellectis Reports Financial Results for the Second Quarter 2026 - GlobeNewsWire
- 17 days ago - Cellectis Earnings release: H1 2026 - Filings
- 17 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 23 days ago - Cellectis to Report Second Quarter Financial Results on August 6, 2026 - GlobeNewsWire
- 5 weeks ago - Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio - GlobeNewsWire
- 2 months ago - Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - GlobeNewsWire